At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 938 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
In Brief
A Phase 3 clinical trial evaluating Tirzepatide and Placebo for Type 2 Diabetes and 2 related conditions. Completed, enrolled 938 participants across 75 sites in 8 countries.
Detailed Summary
This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes, Overweight, Obesity
CountriesArgentina, Brazil, India, Japan, Puerto Rico, Russia, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartMar 2021
Primary CompletionMar 2023
Study CompletionApr 2023
TodayJul 2026
First PostedDec 7, 2020
Enrollment StartMar 29, 2021
Primary CompletionMar 16, 2023
Study CompletionApr 10, 2023
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.6 years ago
Interventions
Tirzepatidedrug
Administered SC
Placeboother
Administered SC